Related Experiment Video
Updated: Mar 12, 2026
08:59
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
8.8K
Update on Brazil's pharma patent landscape.
1Daniel Advogados, Av. República do Chile, 230 - 3º Andar, Centro Rio de Janeiro, RJ, Brasil, Rio de Janeiro 20031-170, Brazil.
Pharmaceutical Patent Analyst
|November 3, 2016
Summary
Brazil's pharmaceutical market, a global top ten player, faces significant patent examination challenges due to backlogs and limited examiners. Efforts are underway to expedite the process for patentees.
Area of Science:
- Pharmaceuticals
- Intellectual Property Law
Background:
- Brazil's pharmaceutical market is a significant global player, ranking within the top ten.
- Patentees in Brazil encounter unique challenges within the intellectual property landscape.
Purpose of the Study:
- To outline the specific hurdles faced by patentees in Brazil's pharmaceutical market.
- To discuss the measures being implemented to address examination backlogs and examiner shortages.
Main Methods:
- Analysis of the Brazilian Patent and Trademark Office's examination process.
- Review of adopted measures to accelerate patent examination.
Main Results:
- The Brazilian Patent and Trademark Office faces a substantial backlog.
- A limited number of examiners contributes to examination delays.
- A two-tier examination system presents unique challenges for patentees.
Conclusions:
- Despite its market promise, Brazil presents considerable patent prosecution challenges.
- The Brazilian Patent and Trademark Office is implementing measures to improve examination efficiency.
- Addressing examiner shortages and procedural bottlenecks is crucial for patentees.
Related Concept Videos
01:26Pharmaceutical Equivalents
244
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
244
01:25Drug Regulation
3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
333
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
333
01:26FDA Approved Drugs: Changes to Approved Drugs
311
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
311
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
397
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
397